Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.50 |
| ▸ | JAK1 | P23458 | 1/20 | 0.50 |
| ▸ | PRMT5 | O14744 | 4/20 | 0.48 |
| ▸ | WDR77 | Q9BQA1 | 3/20 | 0.48 |
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.46 |
| ▸ | STS | P08842 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | YAP1 | P46937 | 2/20 | 0.41 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20515959 | 1.00 | JAK2 (0.50) | JAK2JAK1PRMT5WDR77USP30 | |
| SCHEMBL20515963 | 0.94 | PRMT5 (0.49) | JAK2JAK1PRMT5WDR77USP30 | |
| SCHEMBL18689845 | 0.94 | PRMT5 (0.49) | JAK2JAK1PRMT5WDR77USP30 | |
| SCHEMBL18669285 | 0.86 | SMN1; SMN2 (0.41) | GAASMN1; SMN2 | |
| SCHEMBL18669284 | 0.86 | SMN1; SMN2 (0.41) | GAASMN1; SMN2 | |
| SCHEMBL20503925 | 0.86 | JAK2 (0.55) | JAK2JAK1PRMT5WDR77USP30 | |
| SCHEMBL942191 | 0.86 | JAK2 (0.55) | JAK2JAK1PRMT5WDR77USP30 | |
| SCHEMBL697850 | 0.86 | JAK2 (0.55) | JAK2JAK1PRMT5WDR77USP30 | |
| SCHEMBL29253478 | 0.80 | KDM4E (0.53) | JAK2JAK1PRMT5GPR119STS | |
| SCHEMBL18669297 | 0.80 | LMNA (0.39) | KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10370356-B2 | Pyridinone dicarboxamide for use as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2019-08-06 | — | — | US | disclosed |
| US-10370356-B2 | Pyridinone dicarboxamide for use as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2019-08-06 | — | — | US | disclosed |
| US-20180282301-A1 | PYRIDINONE DICARBOXAMIDE FOR USE AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2018-10-04 | — | — | US | disclosed |
| WO-2017050714-A1 | PYRIDINONE DICARBOXAMIDE FOR USE AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10370356-B2 | Pyridinone dicarboxamide for use as bromodomain inhibitors | BRD4, BRD3, BRDT | JAK2 788/4885JAK1 1998/4885PRMT5 551/4885 |
| US-20180282301-A1 | PYRIDINONE DICARBOXAMIDE FOR USE AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRDT | JAK2 788/4885JAK1 1998/4885PRMT5 551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.